Neurotherapeutic Strategies for Multiple Sclerosis

Teresa C. Frohman; Shin C Beh; Eric J. Kildebeck; Ram Narayan; Katherine Treadaway; Benjamin Greenberg; Elliot Frohman

doi:10.1016/j.ncl.2016.05.001

Neurotherapeutic Strategies for Multiple Sclerosis

Teresa C. Frohman, Shin C Beh, Eric J. Kildebeck, Ram Narayan, Katherine Treadaway, Benjamin Greenberg, Elliot Frohman

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

Original language	English (US)
Pages (from-to)	483-523
Number of pages	41
Journal	Neurologic Clinics
Volume	34
Issue number	3
DOIs	https://doi.org/10.1016/j.ncl.2016.05.001
State	Published - Aug 1 2016

Keywords

Adrenocorticotrophic hormone
Corticosteroids
Disease-modifying therapy
Exacerbation
MS
Multiple sclerosis
Pregnancy

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/j.ncl.2016.05.001

Cite this

@article{fe5a3def01c14615ad500fd9c5c3dd09,

title = "Neurotherapeutic Strategies for Multiple Sclerosis",

abstract = "Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.",

keywords = "Adrenocorticotrophic hormone, Corticosteroids, Disease-modifying therapy, Exacerbation, MS, Multiple sclerosis, Pregnancy",

author = "Frohman, {Teresa C.} and Beh, {Shin C} and Kildebeck, {Eric J.} and Ram Narayan and Katherine Treadaway and Benjamin Greenberg and Elliot Frohman",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.ncl.2016.05.001",

language = "English (US)",

volume = "34",

pages = "483--523",

journal = "Neurologic Clinics",

issn = "0733-8619",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Neurotherapeutic Strategies for Multiple Sclerosis

AU - Frohman, Teresa C.

AU - Beh, Shin C

AU - Kildebeck, Eric J.

AU - Narayan, Ram

AU - Treadaway, Katherine

AU - Greenberg, Benjamin

AU - Frohman, Elliot

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

AB - Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)–approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.

KW - Adrenocorticotrophic hormone

KW - Corticosteroids

KW - Disease-modifying therapy

KW - Exacerbation

KW - MS

KW - Multiple sclerosis

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84992151461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992151461&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2016.05.001

DO - 10.1016/j.ncl.2016.05.001

M3 - Review article

C2 - 27445239

AN - SCOPUS:84992151461

SN - 0733-8619

VL - 34

SP - 483

EP - 523

JO - Neurologic Clinics

JF - Neurologic Clinics

IS - 3

ER -

Neurotherapeutic Strategies for Multiple Sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this